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1. Introduction 
Drug dosing is based on the premise that the amount of drug given influences the toxicity 
and response. The premise of pharmacokinetics is that it is not the amount of drug given, 
but the amount the patient is exposed to, that determines drug effect. Measurements of drug 
exposure are usually performed by determining the concentration in serum or plasma. This 
accounts for variability in drug clearance in determining the patient’s exposure. This has 
resulted in such dosing strategies as carboplatin dosing based on creatinine clearance, 
therapeutic dose monitoring of methotrexate and pharmacogenetically modified dosing for 
irinotecan. 
However it is well recognised that the plasma is not the compartment that is most relevant 
in determining tissue effects. For example for the antibiotic azithromycin the organ 
concentrations in the site of infection, such as lung are the critical feature in determining 
drug effect for pneumonia (Olsen et al., 1996; Schentag & Ballow, 1991). This argument has 
been extended to cancer anti-metabolites (Shewach & Lawrence, 2003). 
The situation in the treatment of a patient with cancer is even more complex. Tumours occur 
in an organ of interest such as the lung, or brain and liver. Regional concentrations in these 
organs are important variables (Reid, et al 1990; Breedveld et al., 2005). However tumours 
also create their own microenvironment with alterations in blood supply, interstitial 
pressure and local secretion of growth factors and cytokines (Liotta & Kohn, 2001; Wiig, et 
al, 2010). The drug concentration of interest is the concentration at the tumour site. 
Differences in tissue PK (C. Presant et al., 1990) and inter-tumoural and intra-tumoural PK 
are additional considerations (Zamboni et al., 2002). Therefore variation in the 
pharmacokinetics of plasma is only one source of variation between patients. 
The reason why plasma is sampled is, of course because it is easily accessible. There are 
limited possibilities for repeated tumour biopsies, although this has been done (Eisbruch et 
al., 2001) and although there are some techniques for sampling closer to the tumour such as 
microdialysis (Jain, 1987), nuclear magnetic resonance spectroscopy (Müller et al., 1997) and 
positron emission tomography (Gupta et al 2002) these have had limited application. 
Nevertheless it is important to recognise the limitations of plasma and aim for sampling 
closer to the target where possible. 
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A special case is that of intra-cellularly activated drugs. The most important class of these 
drugs in oncology are the nucleoside analogues such as ara-C, fludarabine and gemcitabine. 
In this situation the drug administered is a pro-drug, which is activated intracellularly. 
Because the enzymatic pathways required for drug activation are well characterised there is 
therefore an excellent opportunity to move the consideration of drug pharmacokinetics one 
step closer to the target, by considering intra-cellular pharmacokinetics. 
The pharmacogenetics of gemcitabine are summarized with a curated bibliography at 
PharmGKB. The reader is also referred to previous reviews for more detailed reports 
(Danesi et al., 2009; Galmirini et al., 2001; Nakano et al., 2007; Veltkamp et al., 2008). The 
purpose of this chapter is to bring together the data on pharmacokinetics, pharmacogentics, 
pharmacodynamics and associated models to provide a worked example of the potential for 
integrating this information and the utility and limitation of moving one step closer to the 
target. 
2. Gemcitabine background 
Gemcitabine (GEM) is a deoxcytidine analogue (2′,2′-Difluorodeoxycytidine) which mimics 
the normal actions of the pyrimidine nucleoside deoxycytidine in its transport, 
phosphorylation to the tri-phosphate and then incorporation into DNA. Its structure is 
shown in Figure 1. However during DNA synthesis only one further base can be added then 
the DNA polymerase is unable to pass the altered base and DNA chain termination results. 
This causes an S-phase specific cell cycle arrest and programmed cell death (P. Huang, et al, 
1991).  
 
Fig. 1. Chemical structure of Gemcitabine (Creative commons license Wikimedia commons)  
The enzymes responsible for each step of these processes are well characterised and 
variation in their activity are potential causes of variation in the response to GEM. Details on 
each gene of interest are provided on the entrez-gene link provided. Understanding which 
steps are causes of variation in toxicity and response and how to model the effects of 
multiple variables are key issues in understanding this variation. This requires 
understanding the relationship between the pharmacokinetics of GEM in the plasma and the 
intracellular activity of gemcitabine triphosphate (GEM-TP). The pathway of GEM 
activation and inactivation is illustrated in Figure 2. 
The importance of understanding this is underlined by the fact that GEM is a commonly 
used drug in a wide range of important cancer types including non-small cell lung, breast, 
pancreatico-biliary and bladder. 
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Fig. 2. Gemcitabine pathway (copyright PharmGKB, permission has been given by 
PharmGKB and Stanford University) 
2.1 Uptake 
The first step in activation is an active process of transport into the cell. The main 
mechanism of uptake is via hENT1 (SLC289A1) (Mackey et al., 1998) although a smaller 
portion is carried via other transporters SLC28A1 and SLC28A3 (Graham et al., 2000).  
2.2 Phosphorlyation 
Intracellular retention requires phsophorylation via the kinases, deoxyctidine kinase (DCK) 
and CMPK1. The rate- limiting step in this process is DCK. Phosphorlyation promotes 
intracellular retention and allows incorporation of GEM-TP into DNA. 
2.3 Inactivation 
The major route of inactivation is via deamination via Cytidine deaminase(CDA). CDA is 
ubiquitously expressed and converts GEM to difluorodeoxyuridine (dFdU). dFdU has low 
level activity and is water soluble and excreted almost entirely by renal excretion. A minor 
route of deactivation is through dephosphorylation of GEM-TP via 5’Nucleotidase 
(Dumontet et al., 1999). 
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2.4 Self- potentiation 
One of the remarkable aspects of GEM pharmacology is that it has multiple mechanisms of 
self-potentiation (W Plunkett et al, 1996). The most important mechanism is that GEM-TP 
and GEM-DP block the salvage pathway of nucleotide synthesis through inhibition of 
Ribonucleotide reductase. This has the effect of reducing the pool of nucleotides that are 
competing with GEM-TP for incorporation and thereby increasing GEM-TP incorporation 
into DNA. Ribonucelotide reductase is composed of 2 subunits RRM1 and RRM2. The 
importance of this pathway is underlined by the data that variation in RRM1 is a critical 
determinant of GEM response (see later). 
A second mechanism of self-potentiation occurs via inhibition by GEM of dCMP deaminase, 
which results in a reduced catabolism for GEM-TP (Heinemann et al., 1992) and a third 
mechanism of self-potentiation is that the main metabolite of GEM, dFdU (Hodge, et al,, 
2011) increases GEM-TP accumulation in a time dependent manner. 
3. Pharmacogenetics of GEM 
There is considerable inter-patient variability in gemcitabine accumulation and there are 
polymorphisms described in many of the genes involved in transport, activation and 
inactivation. Data on pharmacogenetics for key drugs is agregated on the PharmGKB wesite 
(http://www.pharmgkb.org) and gemcitabine is included in this collection. An excellent 
review has been published by Wong et al (2009). 
3.1 Understanding the significance of polymorphisms 
Understanding the significance of a polymorphism will depend upon its changes in 
structure, functional significance and the frequency of variation. Non coding SNP’s can be 
associated by chance, by linkage disequilibrium or potentially through influences on , 
alternate splicing, microRNA binding or DNA morphology. Changes in the promoter region 
can lead to variation in expression. The significance depends more fundamentally on the 
impact that the coded protein has on function. There are two issues here –how much does 
each gene product impact on function and how much of human variation is accountable by 
variation in this gene. 
For example there are 23 snp's in the gene SLC28A3 in the dbnsnp database 
http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=64078 . Of these most are very 
infrequent with the heterozygozity rate of 15 loci are > 1% and only 6 are > 5%. Of the six 
most frequent SNP’s, 3 are synonymous. These considerations are complicated by the issue 
that infrequent polymorphisms with major effects on function can have severe 
consequences. 
Understanding the functional importance of a hapoltype or SNP ultimately requires 
demonstration of an effect on toxicity or efficacy. Pharmacokinetics however plays a crucial 
intermediate role in mediating pre-target variation. An association between a genetic 
variation and pharmacokinetics of the drug greatly increases the pre-test probability that 
functional differences will be found that are not related to chance. 
3.2 CDA 
A summary of SNP’s in CDA is found in the geneview of the dbDNP database. 
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In European populations CDA:79A>C ( K27Q)  where the C allele is seen with a frequency 
of 0.36. Patients with a copy of the variant  allele have reduced clearance and increased 
haematological toxicity. In Japanese patients this SNP is uncommon but a less common 
variant G208A has been associated with markedly reduced clearance and increased toxicity. 
The comparison between the two SNP’s shows the importance of both common variations 
(in contribution to interpatient variability) and uncommon but functionally very important 
variants in contributing to toxicity “outliers”. 
3.3 RRM1 
A summary of SNP’s in RRM1 is found in the gene view of the dbSNP database. RRM1 is of 
particular interest because there is strong data to support the influence of mRNA protein 
expression on survival in patients with NSCLC treated with gemcitabine (Ceppi et al., 
2006)(Rosell et al., 2004). The data supporting a relationship between RRM1 polymorphisms 
is not as strong. There are two relatively common polymorphism in the European 
population c.2223A>G and 2464G>A with minor allele frequencies of 0.5 and 0.16 
respectively. The 2464G>A has been shown to be associated with GEM sensitivity in vitro 
(Kwon et al., 2006)and haplotype is associated with response (but not survival) in patients 
with NSCLC treated with GEM (Kim et al., 2008). A small study suggested a relationship 
between -37C>A and progression free survival (PFS) (S. Dong et al., 2010).  
3.4 hENT1 
In patients with pancreatic cancer treated with gemcitabine hENT1 transcript levels were 
associated with survival (Giovannetti et al., 2006). However identified polymorphisms are 
infrequent (SNP:Geneview) and 201A>G has been identified with increased neutropenia 
(Tanaka et al., 2010). Sugiyama found no relationship with gemcitabine pharmacokinetics 
(Sugiyama et al., 2001) 
Polymorphisms of other potentially important genes such as other transporters and DCK 
have not yet been shown to have clinical importance.  
3.5 Haplotypes 
There is a growing view that polymorphism in single genes are unlikely to be informative 
and that more relevant information is likely to come from sets of informative genes 
(haplotypes)(Kalow, 2006) or more complex genetic variations (Lee & Morton, 2008). 
Because of linkage disequilibrium, some combinations will occur more frequently than 
others and it is therefore possible to map the most common gene combinations and test their 
significance.  
This approach has been taken with CDA in the Japanese population where one haplotype 
(of various CDA SNP’s) termed *3 was associated with reduced clearance of gemcitabine 
and increased toxicity (Sugiyama et al., January 2010).  
Tanaka et al have taken a comprehensive approach (Tanaka et al., 2010; Okazaki et al, 2010). 
They first screened 17 polymorphisms in relevant (CDA, dCK, RRM1, hCNT2, hCNT3, and 
hENT1) genes in a sample of 149 patients with pancreatic cancer receiving chemo-radiation 
and identified polymorphisms with significant associations for toxicity or trends for effects 
on survival. None of the SNP’s singly was associated significantly with survival. 
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They then went on to examine the relationship between SNP's and identified that two or 
three SNPs each of the dCK, RRM1, hCNT2, hCNT3, and hENT1 (IVS12-201A>G and IVS2-
549T>C) genes were in linkage disequilibrium (|D'|>0.5, P < 0.01). This enabled 
identification of relevant haplotypes. 
They next examined relationships between haplotypes and overall survival (OS). The CDA 
C111T and A-79C TA haplotype was significantly associated with increased risk and the 
hENT1 A-201G, T-549C, and C913T ACT haplotype was significantly associated with 
reduced risk of death compared with the most common haplotype of each gene respectively 
(P < 0.05). 
They were also able to examine the effects of gene dose by comparing outcomes according 
to the number of poor risk genotypes. Patients carrying 0 to 1 (n = 43), 2 to 3 (n = 77) or 4 to 6 
(n = 30) variant alleles had a Median Survival time T of 31.5, 21.4, and 17.5 mo, respectively. 
This work shows the need to consider multiple significant genes in determining significance 
and the added power this analysis brings. However as discussed below there are 
fundamental limitations to the SNP approach, that relate to the relationship between 
genotype and phenotype. 
3.6 Considering the influence of transcription and translation 
One of the limitations of focusing on genetic polymorphisms as causes of functional 
variation is the potential influence of gene silencing (Meister & Tuschl, 2004) transcriptional 
(Goth-Goldstein et al, 2000) and post transcriptional regulation on protein expression (Cress 
& Seto, 2000). DNA sequence is only one determinant of ultimate function. Genes can be 
silenced by methylation or acetylation, alternate splicing of gene transcripts can lead to 
differences in function and allelic imbalance can lead to increased expression. 
Environmental influences on transcription such as inhibition or induction by drugs or 
endogenous messages are critical. One way of accounting for these variations is to 
concentrate on measurement of phenotype rather than genotype (Mahgoub et al, 1977).  
With CDA phenotype has been assessed ex vivo by incubation of mononuclear cells, plasma 
or red cell extracts with pyrimidine analogues and measurement of deamination.  
Similarly a furthers study found phenotype as assessed by in vitro deamination correlated 
with toxicity whereas specific polymorphisms did not (Ciccolini et al., 2010; Mercier et al, 
2007) 
4. Challenges in measurement of intracellular PK 
There are a number of challenges in the measurement of both GEM and the intracellular 
metabolite GEM-TP. The first of these is related to the fact that CDA is present in plasma, 
therefore every blood collection tubes requires the presence of tetrahydrouridine (THU) to 
inhibit CDA. If THU is not included all of the GEM will be converted to dFdU its inactive 
metabolite in plasma before it can even enter the cell to be converted to the active metabolite 
GEM-TP. The next challenge is the fact that white cells cannot be stored frozen without the 
loss of triphosphates, therefore the triphosphates need to be extracted from leucocytes 
before any of the sample is frozen. This is not a complex processes but does require time and 
some experience is necessary thus can not easily be performed by a nurse that generally 
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collects the blood samples and adds to the complexity of the studies and probably the main 
reason why more intracellular measurements are not routinely conducted. The amount of 
leucocytes present in an individual blood sample is highly variable and can be effected 
markedly when patients are on chemotherapy. While the analysis of GEM and dFdU in 
plasma are relatively straight forward and can be quality controlled and give reliable 
results, the same cannot be said about the assay used to measure GEM-TP. This involves the 
use of an ion exchange column and high concentrations of salt to remove the triphosphate 
from the column. This makes the assay difficult to convert to more sensitive LCMS assays. It 
is not easy to quality control this assay which could lead to varying data being reported by 
different laboratoties. 
5. Pharmacokinetics and dose optimisation 
The pharmacokinetics of plasma Gemcitabine and its main metabolite have been described 
in multiple studies. The findings of the original phase 1 remain typical (JL Abbruzzese, et 
al., 1991). 77% of Gemcitabine was metabolised to dFdU and excreted in the urine in the first 
24hrs dFdU clearance was proportional to creatinine clearance. The clearance of 
Gemcitabine in the plasma was rapid with a T1/2 of 8 mins. The clearance of GEM was 
independent of dose. The pharmacokinetics of GEM in some representative studies are 
shown in Table 1. 
 
 
Clearance 
(L/h/m2) 
T1/2 min AUC(μM*min) Vss (L) CMax(μM) 
 Soo et al., 2006      
Arm A (n29) 
FDR 
164.0±64.0 18.2±4.2 1,346 ±1113 65 ± 37 21 ± 17 
Arm B (n=29)  
30 min 
181.6±74.5 17.1±3.1 1,432 ±529 75 ±41 41 ± 14 
Tempero,   
et al., 2003 
     
FDR     26  ± 6 
Standard  
(higher dose) 
    100 ± 19 
Grimison,  
et al 2007 
     
FDR n=31   1279±629  19± 6 
Standard n=30   1642 ± 796  50± 18 
Table 1. Representative Plasma Pharmacokinetic Data 
The major clinical determinants of clearance are size and gender. The influence of size has 
been demonstrated through a correlation with BSA, which justifies the use of BSA to adjust 
dose. The influence of gender has been more variable although some studies show reduced 
clearance in women.  
There is much less data on the pharmacokinetics of GEM-TP. Data from some representative 
studies are shown in Table 2. In the early development of Gemcitabine it was identified that 
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exposed cells demonstrate saturable accumulation of the Triphosphate. This correlates with 
the biochemistry of accumulation and retention being limited by intracellular conversion to 
the Triphosphate by DCK.  In phase 1 studies this translated to a saturation of Gemcitabine 
accumulation in mononuclear cells with increasing dose. This is accompanied by a change in 
the pattern of elimination with monophasic elimination at low concentrations and biphasic 
elimination described after the threshold has been reached. 
 
 
Clearance 
(L/h/m2) 
AUC(μM*min) CMax(μM) 
Soo et al., 2006    
Arm A (n29) FDR 5.2±2.0 35 079±18 216 174 ± 77 
Arm B (n=29) 30 min 7.0±2.61 32 249±11 267 225 ± 74 
(Tempero,  et al., 2003)    
FDR   398 
Standard (higher dose)   188 
 (Grimison, et al 2007)    
FDR n=31  2600 ± 2483   
Standard n=30  1833± 1833  
Table 2. Representative Intracellular Pharmacokinetic Data 
The clinical correlate of this finding is that accumulation can be maximised by prolonging 
infusion time and indeed this is the case. Based on accumulation in leukemic blasts a target 
concentration and rate of administration was determined to maximise accumulation. There 
are several problems with this process. The target concentration and optimal rate of infusion 
has not been determined in solid tumours, where the kinetics are known to be different. 
Secondly the “optimum” rate of administration does not take into account inter-individual 
variation. Differential expression of DCK between tumours and normal tissue and between 
individuals would be expected to determine different optimum rates of administration. 
The rationale for prolonged dosing received a major boost when a randomised phase 2 
study demonstrated proof of principle that in a clinically relevant scenario (pancreatic 
cancer) prolonged infusion at a rate of 10 mg/m2/min (compared to a standard 30 min 
infusion) was associated with not only increased accumulation of GEM-TP, but with a trend 
for increased survival. This lead to a proliferation of similar studies in other tumour types 
confirming the pharmacokinetic finding but underpowered to demonstrate survival 
differences. Unfortunately a large phase 3 study, in pancreatic cancer, demonstrated that the 
pharmacological advantage obtained failed to translate into a significant survival advantage.  
The challenges in optimising accumulation of Gemcitabine have been highlighted by data 
from our group showing an increase in Gemcitabine accumulation between week 1 and 2 
with weekly administration (Grimison, et al., 2007). This suggests auto induction of 
Gemcitabine accumulation. In vivo modelling suggests this is a generic response to DNA 
damaging agents (Metharom, et al, 2010). The significance of this increase is not certain, 
with one study showing a non significant increase (de Lange et al., 2005), but it potentially 
complicates strategies to achieve a target intracellular concentration if the target changes 
over time.  
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We have furthered examined potential explanations for the discordance between the 
pharmacological advantage seen previously and the negative phase 3 study. Analysis of 
SNP’s from our study has suggested that the pharmacological advantage of prolonged dose 
rate Gemcitabine is restricted to patients with the variant allele of c.CDA79A>C (Metharom 
et al., 2011). If this finding is confirmed, then the phase 3 study would have been 
underpowered to detect a survival difference in this population and consideration of the 
optimum dosing schedule may require individualisation according to genotype. 
5.1 Pharmacokinetic/Pharmacodynamic relationships 
The availability of pharmacokinetic data for both the prodrug and the active intracellular 
metabolite leads to the possibility of exploring differences in the ability of these parameters 
to predict drug effects of toxicity and efficacy. 
There is data that demonstrates correlations between the concentration of Gemcitabine at 
the end of the infusion and haematological toxicity, however the relationship is weak. There 
is very limited data exploring the relationship between the pharmacokinetics of intracellular 
GEM-TP and toxicity. No relationship was seen in combination with Carboplatin ( Soo et al., 
2006) In our data GEM-TP cMax correlate with AUC and was used for pharmacodynamic 
correlations. Modelling GEM-TP concentrations to % reduction in white cells improved the 
fit of the model although the relationship remained modest (r2 = 0.3739) (Grimison et al., 
2007). This provides proof of concept that moving from the plasma to intracellular 
compartment did improve predictive ability, but that the proportion of variance related to 
pharmacodynamic variability and the relationship of the sampled compartment to the 
compartment of interest will determine the utility of this approach. 
The relationship of pharmacokinetics to tumour response is much more difficult to assess as 
tumour Reponses are heterogeneous and seen in a minority of patients treated with 
Gemcitabine. This then requires PK sampling in large populations of patients, which is 
unattractive to designers of clinical trials and enrolled patients. As a result there are no large- 
scale studies correlating clinical benefit, response or survival endpoints with PK parameters. 
Reported pharmacokinetic/pharmacodynamic relationships are summarised in Table 3. 
 
Treatment Tumour n variable Finding 
Carboplatin and FDR  
GEM 
(Wang et al., 2007)
NSCLC 21  
% reduction WBC and 
GEM-CMax 
R2= 0.4575 
   
% reduction plat  and 
GEM CMax
R2= 0.5671 
Paclitaxel GEM 
(Fogli et al., 2001)
  
% reduction plat and 
GEM CMax
 
High dose GEM and 
autologous stem cells  
(Bengala, et al., 2005)
pancreas 23 
Mononuclear CDA 
activity and 
expression
Low activity 
/expression associated 
with response 
Gemcitabine and RT   
(Eisbruch et al., 2001) 
Head and 
neck 
29  
Poor correlation 
between dose and 
tumour concentration   
Table 3. Pharmacokinetic/Pharmacodynamic relationships 
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6. Population models of Gemcitabine PK 
6.1 Population PK models 
Pharmacokinetic models are a mathematical shorthand way of describing PK data. In the 
most common approach to estimation of pharmacokinetic parameters, data from an 
individual is used to fit to a model and calculate variables such as clearance. Individual 
estimates of clearance then describe the population. In the population pharmacokinetic 
approach the data from the whole population is used to develop the model parameters and 
calculate variables, like clearance. The population approach is more complicated and 
requires more computing and human resources but has several advantages including the 
handling of sparse data. It is well positioned to include other co-variates in the model 
development such as clinical parameters (age, BSA, measure of renal or hepatic function) as 
well as novel laboratory measures. In both cases the model “compartments” are 
mathematical constructs rather than physiological compartments. Population PK modelling 
does lend itself to conforming the model to physiological compartments, which may also be 
sampled, such as plasma or an intracellular compartment. For a review of population PK 
modelling of anticancer agents the readers is referred to the review by Zandvliet et al.  
(2008). 
6.2 Population PK models for Gemcitabine  
There are 3 reported population pharmacokinetic models for plasma Gemcitabine and dFdU 
and one model that includes GEM-TP. Each GEM model fits for a 2 compartment model 
with a presumed peripheral and central compartment. Jiang et al derived our model from 94 
patients with various malignancy treated on PK studies. Sugiyama et al derived a model 
from a population of 250 Japanese patients included in previous PK studies. Zhang et al 
derived their model from the data from original phase 1 studies. The model parameters for 
all three models are summarised in Table 4.  
 
Study Compartments CL L/min VC (l) VP RV 
STG 2 2.7 (31%) 15 (39%)  40 
Sugiyama *  1.24  12.6 9.54  
Zhang  2 NR NR NR  
Pham 2 5.1 2.96 47.6 35 
CL=clearance; VC= volume central compartment VP = volume peripheral compartment and  
RV = residual variation 
*calculated assuming a BSA of 1.78, Cr=100mg/dL age 62.67 and median values for male and female 
Table 4. Parameters from Gemcitabine Population Pk Models.  
The models allow some significant observations. Significant covariates included in the final 
version of all models include BSA, age and sex. This confirms univariate observations from 
individual PK data. The inclusion of BSA is an important observation given the debate over 
whether clinical doses should be adjusted for BSA for anticancer drugs. 
The models also allow evaluation of potential drug interactions with co-administered drugs. 
The Jiang model compared the impact of co-administered of oxaliplatin with a 35-45% 
decrease in the Vc for dFdU. 
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The patients in the Sugiyama paper were administered a variety of partner drugs and this 
allowed evaluation of potential interactions. They were able to demonstrate a 20% increase 
in the clearance of GEM following S1, a potentially clinically relevant observation. The 
speculative mechanism is an increase in hENT1 expression. This demonstrates the relevance 
of considering intracellular pharmacokinetics because an increase in clearance into the 
intracellular compartment (which is greater in tumours) has a different implication to an 
increase in clearance due to increased excretion. A summary of findings of each model for 
significant covariates is given in Table 5. 
 
Author n Examined  Significant Comments 
Sugiyama  248 
(BSA), weight, age
and sex and co-
administered 
drugs, cisplatin, 
carboplatin, 
fluorouracil, S-1, 
vinorelbine 
Including BSA 
improved modelling 
of clearance  
 
 S-1 significantly 
increased CL  
Age and sex did not 
significantly affect the 
CL and V1 of 
Gemcitabine. 
Zhang  353 
age, sex,(BSA), 
type of cancer, 
renal function, 
rate, and 
duration of 
infusion, plasma 
CDA activity 
BSA on Clpc, 
Vpc,and Vpp,gen- 
der on Clpc and 
Vpc,ageon Clpc, and 
duration of infusion 
on Vpp. 
Note plasma CDA 
not significant 
Tham 56 
age, body size, 
(KPS), stage, 
creatinine 
clearance, sex, 
race, and 
Smoking history. 
Weight and height 
No improvement 
with allometric 
scaling; fat content 
can be ignored when 
using size variable. 
The influence of sex 
disappeared when 
considering lean 
body mass 
Table 5. Co-variates examined versus included in GEM models 
6.3 GEM Pop PK including pharmacogenetic variables 
The Sugiyama model also investigated the influence of several pharmacogenetic variants in 
the Japanese population. They had previously reported a variant CDA 208G>A (associated 
with the*3 haplotype) with a minor allele frequency of 0.022 in the Japanese population as 
associated with increased toxicity in homozygous patients (Sugiyama, et al., 2009). 
They investigated the role of this other polymorphisms in CDA, DCK and hent1 (SLC29A1) 
and evaluated included the following found common polymorphism in the base model 
CDA A79>C variant (allele frequency 0.208); –31delC (0.44); 2 polymorphisms in the hENT 1 
gene–3797A>G (0.398) and –3268_–3249del AGGCTCGCGAGCGGAGGTGC (0.398). The 
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significance of the final model was driven by CDA*3 , although -31delc and CDA A79>C 
also contributed. The significance of the *2 haplotype in the absence of *3 (as is seen in 
Caucasians) is not clear from their model. 
One interesting piece of data relating pharmacogenetic and PK comes from a very simple 
study where the deamination rate of red cell extracts was measured and correlated with 
genotype (Giovannetti et al., June xx 2008). Mean enzymatic activity was significantly lower 
in patients carrying the CDA Lys27Lys than in patients with the Lys27Gln or Gln27Gln 
protein. This highlights the potential of measuring activity in accessible targets (such as ex-
vivo plasma) to model phenotype, and explores phenotype-genotype correlations. 
6.4 Population PK including intracellular GEM-TP 
Zhang et al were able to extend the population model to include estimation of GEM-TP. 
They used the existing plasma GEM model and added an extra compartment (the 
intracellular compartment). GEM-TP concentrations were explained by a simple Michaelis- 
Menten formula. No additional parameters were investigated and the Km was fixed at the 
median value and the infusion rate was fixed at 10mg/m2/min. 
(Tham et al., 2008) also derived a population PK model with intracellular compartment by 
adding an extra compartment to the Gemcitabine plasma 2 compartment model. They 
concluded, in comparison, that the GEM-TP was equally as well explained by a linear 
model, and therefore saturable metabolism did not occur. Interpretation of their data is 
complicated because it appears that fixed dose rate and standard dose rate Gemcitabine data 
has been lumped together despite previous data that saturation only occurs with the 
standard dose rate regimen. 
The disparity in interpretations also highlights the assumptions brought to bear in selecting 
pharmacokinetic models. Tham et al have selected the most parsimonious model and 
concluded that there was no evidence to support a saturable model; Zhang et al have fitted a 
Michaelis-Menten model based on previous data and found that it describes their data 
adequately. This reflects a basic debate about whether science is assumption free. Karl 
Popper has eloquently argued that all science is based on assumptions. Rejecting the 
saturable PK model on the basis of lack of improvement in the objective variable should not 
be taken to mean that saturable metabolism does not occur, just that in this data set the 
model did not improve performance.  
6.5 Physiological modelling 
A very sophisticated approach has been taken by (Battaglia & Parker, 2011) they have 
constructed an intracellular accumulation model based on existing plasma PK models. They 
have created a physiological based model of Gemcitabine intracellular accumulation with 
initial estimates based on cell line measurements. They have modelled each of the 
parameters as first order but the overall model produces saturable metabolism due to the 
interactions built in. The model includes a variable for the dose rate and includes such 
physiologic processes as self- potentiation and cell cycle specificity, and diffusion through 
the interstitial space into solid tumours. 
This work demonstrates the potential of combining measurement of clinically relevant 
compartments with an understanding of the biology involved. One application of such 
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models is that it can be used to drive clinical trial design to determine the optimum 
conditions for maximising tumour exposure under a variety of circumstances. This can 
potentially lead to more efficient clinical trial design. 
6.6 Modelling of response 
The relationship of pharmacokinetics to response is much more difficult to assess as tumour 
reponses are heterogeneous and seen in a minority of patients treated with Gemcitabine. 
This then requires PK sampling in large populations’ of patients, which is unattractive to 
designers of clinical trials and to enrolled patients. There is however one very interesting 
attempt to do this in the literature. Data from a randomised phase 2 study of fixed dose 
versus standard dose rate administration of Gemcitabine was used to provide PK data and 
measurements of individual tumours. The pharmacokinetic parameters were estimated 
from the previously derived 4 compartment population model. The tumour effect 
compartment was then modelled according to a delayed exposure to estimate tumour 
exposure. The inhibitory effect of drug exposure on tumour growth was then modelled 
(from the change in size of the tumour) by a Gompterzian tumour growth model. The 
impact of drug exposure on tumour inhibition was then tested by Emax, or sigmoid Emax, 
models with exposure estimated by either dose or estimated AUC. In the final model using 
Intra-cellular GEM-TP AUC did not improve the fit over using Gemcitabine dose. 
Interestingly the dose response variability of 146% was much greater than the interpatient 
variability in Gemcitabine clearance, suggesting that a target concentration approach would 
not be helpful in dose individualisation. 
This work represents a “heroic” attempt to take the PK/PD modelling to its logical extreme, 
however the interpretation of the observation that intra-cellular GEM-TP did not improve 
the –prediction of response should be coloured by a realisation of the limitation of the 
model. Firstly the PK model, the tumour growth model and the final PK/PD model are all 
based on data from a relatively small number of patients. Secondly the measurements that 
they are based upon e.g. GEM-TP and tumour size –have relatively large errors. Thirdly the 
three inter-related models are all based on the assumptions outlined in the paper. Many of 
these are unlikely to be true, such as the independence of Gemcitabine and Carboplatin. 
Finally the significance of the observation that a particular co-variate does not improve the 
fit of the model does depend on the overall fit of the model. Obviously a very poor model 
will not be sensitive to variations in the inputs chosen; it will perform equally well – or 
equally poorly. In this regard the overall model has very wide confidence interval the 
median tumour size at 12 weeks is approximately 4cm with a 95% confidence interval of 2.5-
12cm, clinically very significant differences. The relevance of the Gomptzerian model is also 
in question as it is now very clear that a major part of the benefit of cytotoxic therapy relates 
to the achievement of prolonged stable disease and tumour dormancy rather than tumour 
response. Nevertheless this work is a very exciting demonstration of the possibilities of 
incorporating tumour response into well understood pharmacokinetic models.  
6.7 Discussion 
These data demonstrate some of the possible applications of a population PK approach. The 
limitations of each model also demonstrate the potential of using models, which are one step 
closer to the source. 
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The Sugiyama model is a very exciting step towards the incorporation of pharmacogenetic 
data to inform model development. Any pharmacogenetic model will be constrained by the 
population it is developed in hence the dominant effect of the *3 mutation, which is 
extremely infrequent in the Caucasian population, may obscure the effects of other 
polymorphisms in other populations. 
The major step towards developing a physiologically based model would be to apply the 
polymorphisms to the model in a physiologically informed way. CDA is going to be the 
main determinant of plasma clearance, so its incorporation into the elimination from the 
central or peripheral compartment is most relevant. However DCK and hENT1 are 
determinants of uptake into the intracellular compartment. The greatest potential then 
would be to model them as variants of the transfer into the intracellular compartment. 
A further step towards more informative models would be to use preclinical data to inform 
initial model parameters for variables such as the relationship between GEM-TP 
accumulation and drug concentration.  
7. Discussion and future directions 
Gemcitabine provides a model for the study of intracellular pharmacokinetics as a way of 
moving one step closer to the target. The improved correlation of GEM-TP 
pharmacokinetics with pharmacodynamic endpoints such as dose reduction or leukocyte 
nadir is proof of principle that this provides important additional information. Given the 
accessible nature of this compartment it is difficult to see why correlative studies should 
continue to pursue plasma pharmacokinetics as an endpoint. 
However the data presented also demonstrates the limitations of intracellular-
pharmacokinetics. The tissue sampled in this literature is leucocytes, which are presumed to 
be a surrogate marker of normal tissue and or tumour uptake. The correlation with other 
normal tissues is the less problematical assumption, as the genotype is the same. It is worth 
considering in what ways leucocytes are different from other target tissues such as bone 
marrow progenitor cells.  
Firstly the regulation and expression of genes is tissue specific with upregulation of DCK 
and CDA in tumour tissue (Spasokoukotskaja et al., 1995; van der Wilt et al., 2003). Lack of 
correlation between genotype and phenotype is an issue with highly regulated genes such 
as CYP450, which are induced and inhibited by drugs and environmental exposures (Shiran 
et al., 2003). Secondly issues around tissue penetration into compartments such as the CSF, 
brain, etc are highly relevant for tumour metastases. Finally the tumour microenvironment 
is one that provides multiple barriers to drug access such as tumour hypoperfusion, 
increased interstitial pressure (Willett et al., 2004) and stromal reactions around 
tumours(Minchinton & Tannock, 2006). There is some evidence that these factors are critical 
in determining intratumoral and intertumoural heterogeneity in drug exposure (Zamboni et 
al., 2002; C. A. Presant et al., 1994).  
Even given these limitations there are still a number of significant opportunities 
associated with the ability to measure pharmacokinetics in the intracellular compartment. 
The first is the ability to assess the clinical significance of availability in genes of known 
importance. As summarised above there are a great number of potential sources of 
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variability in intracellular Gemcitabine uptake. However the source of human variability 
in uptake is an empirical question. Early pharmacogenetic evidence already suggests that 
this may be population specific (Fukunaga et al., 2004). Measurement of intracellular 
pharmacokinetics allows questions to be asked regarding correlation between variation in 
genes such as CDA and intracellular uptake. The time taken to perform studies with 
surrogate makers such as intracellular uptake is much shorter than those requiring clinical 
endpoints such as survival. This allows prioritisation of potential markers for prospective 
validation. 
A second possibility for the utility of intracellular pharmacokinetics is in the development of 
strategies for therapeutic dose monitoring. Moving closer to the target increases the 
possibility of developing an effective TDM strategy. However data from pharmacodynamic 
modelling suggest the greater part of interpatient variability comes from pharmacodynamic 
variables suggesting limited value from pharmacokinetic monitoring (Tham et al., 2008). 
Related to this is a third possibility of pharmacogenetically derived dosing where known 
polymorphisms in genes of interest affects the dose or scheduling of the drug administered 
(Ciccolini et al, 2011). 
A significant challenge relates to application of pharmacogenetic strategies where drugs are 
given in combinations. This requires a clear understanding of the effects of the drugs on 
each other, for example the effect of DNA damaging agents on Gemcitabine accumulation 
(Metharom et al, 2010) and the conditions under which drugs act synergistically (Luk et al, 
2011).  
Optimising the dosing of Gemcitabine according to a rational understanding of an 
individual patients threshold for saturation of GEM-TP is a rational strategy for reducing 
toxicity and improving efficacy. 
A conventional strategy for optimising dose is to build upon a population pharmacokinetic 
model where clinical or laboratory variables of interest are correlated with clinical outcomes. 
The next step with such a model would be to incorporate pharmacogenetic variables of 
interest such as measurement of CDA genotype of phenotype. Determining the coefficients 
by which the impact of such variables can be adjusted will require very large clinical 
studies. Intracellular PK measurements offer the possibility of providing initial estimates of 
such variables from smaller correlative studies both in vivo and in-vitro. The advantage 
over other scenarios such as liver oxidation or glucuronidation is that the genes are 
measurable and the pharmacokinetic intermediate is assessable. This is an important area of 
inquiry to lead us to a goal of a pharmacogenetically guided individualised dosing strategy. 
These strategies are of course complimentary to those aimed at measuring drug distribution 
directly in tissues of interest by the use of tracer radio-pharmaceuticals, microdialysis, NMR 
or PET. The common theme is that facilitating the contribution of pharmacokinetics to 
optimising drug administration in oncology requires us to move closer and closer to the 
target of interest. A variety of techniques to measure intracellular uptake as well as tissue 
penetration and access to the tumour microenvironment are likely to be required to 
minimise the effect of drug variability on the response to anticancer treatments. Combining 
mesurement of more relevant compartments with physiologic modelling and incorporation 
of pharmacogenetic variation, raises a real possibility of predicting drug response in a way 
that realises the hopes of individualised medicine. 
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8. Appendix 
Background information on Single Nucleotide Polymorphisms 
 
Finding information 
The NCI maintains a database of polymorphism (dbSNP) 1 
 
Nomenclature 
Polymorphisms can be referred to by their unique identifier (rs number)   
but are preferably described at the DNA level2 for example 
Rs2072671 describes the polymorphism CDA c.79A>C   
 which occurs in the CDA gene:  
 where the c stands for coding sequence;  
 79 is the first nucleotide affected;  
 and the nucleotide A is substitute for C.  
This results in a protein change described as p.K27Q where the p stands for protein and the 
K and Q are exchanged at the 27th amino acid position. Nomenclature for haplotypes 
becomes more complicated. Because of the sometime complicated nomenclature for 
complex polymorphisms or haplotypes they are usually given nicknames e.g. *1, *2 etc. 
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